Linezolid resistance in a clinical isolate of Staphylococcus aureus.

By S. Tsiodras, H. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. Moellering, M. Ferraro. The Lancet, 2001

1,029 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “Novel classes are clearly needed for MRSA, because current drug classes exhibit treatment-limiting toxicities and emerging resistance [56–58].”
Trends in antimicrobial drug development: implications for the future. (2004, background): “aureus [67] and Enterococcus [68, 69], and multidrug-resistant gram-negative rods [70–74] may result in limited treatment options for skin, urine, and systemic infections that were formerly readily curable with commonly used antimicrobials.”
The future challenges facing the development of new antimicrobial drugs (2002, background): “Unfortunately, resistance to linezolid has already started to emerg”
Antimicrobial resistance: the example of Staphylococcus aureus. (2003, background): “Cross-resistance has not been noted for linezolid, but at least one clinical isolate has developed resistance during therapy (77).”
Bacterial resistance: origins, epidemiology, and impact. (2003, background): “Nevertheless, linezolid resistance can be selected in vivo, particularly in difficult-to-reach infections, those requiring prolonged therapy and if the drug is underdosed [31, 32].”